These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 24420538)

  • 1. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS; Ziogas J; Campbell DJ
    Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: an experiment with isolated rat hearts].
    Zhang YJ; Bai XJ; Qi ZM; Wang HX
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3350-3. PubMed ID: 16409843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
    Abadir PM; Carey RM; Siragy HM
    Hypertension; 2003 Oct; 42(4):600-4. PubMed ID: 12953015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding.
    Hiyoshi H; Yayama K; Takano M; Okamoto H
    Hypertension; 2004 Jun; 43(6):1258-63. PubMed ID: 15123575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
    Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
    Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
    Liu YH; Yang XP; Sharov VG; Nass O; Sabbah HN; Peterson E; Carretero OA
    J Clin Invest; 1997 Apr; 99(8):1926-35. PubMed ID: 9109437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
    Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury.
    Wang LX; Ideishi M; Yahiro E; Urata H; Arakawa K; Saku K
    Hypertens Res; 2001 Mar; 24(2):179-87. PubMed ID: 11325078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
    Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors.
    Bergaya S; Hilgers RH; Meneton P; Dong Y; Bloch-Faure M; Inagami T; Alhenc-Gelas F; Lévy BI; Boulanger CM
    Circ Res; 2004 Jun; 94(12):1623-9. PubMed ID: 15131008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.
    Campbell DJ; Zhang Y; Kelly DJ; Gilbert RE; McCarthy DJ; Shi W; Smyth GK
    Clin Exp Pharmacol Physiol; 2011 Sep; 38(9):623-31. PubMed ID: 21736602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.
    Wu WP; Chang CH; Chiu YT; Ku CL; Wen MC; Shu KH; Wu MJ
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F929-41. PubMed ID: 20685818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.
    Ye Y; Qian J; Castillo AC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2011 Dec; 25(6):505-15. PubMed ID: 21987107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
    Messadi-Laribi E; Griol-Charhbili V; Pizard A; Vincent MP; Heudes D; Meneton P; Alhenc-Gelas F; Richer C
    J Pharmacol Exp Ther; 2007 Oct; 323(1):210-6. PubMed ID: 17636004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
    Hayashi N; Fujimura Y; Yamamoto S; Kometani M; Nakao K
    Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
    van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
    J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade.
    LeFebvre J; Shintani A; Gebretsadik T; Petro JR; Murphey LJ; Brown NJ
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1261-7. PubMed ID: 17182977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.